Literature DB >> 15369393

Assessment of the consistency of medicinal chemists in reviewing sets of compounds.

Michael S Lajiness1, Gerald M Maggiora, Veerabahu Shanmugasundaram.   

Abstract

Medicinal chemists are frequently asked to review lists of compounds to assess their drug- or leadlike nature and to evaluate the suitability of lead compounds based on their "attractiveness" and/or synthetic feasibility as a basis for launching a drug-discovery campaign. It is often felt that one medicinal chemist's opinion is as good as any other, but is it? In an attempt to answer this question, an experiment was performed in conjunction with a recent compound acquisition program (CAP) conducted at Pharmacia. Historically, the CAP included a review of many thousands of compounds by medicinal chemists who eliminate anything deemed undesirable for any reason. In a review conducted in 2002, about 22 000 compounds requiring review by medicinal chemists were broken down into 11 lists of approximately 2000 compounds each. Unknown to the medicinal chemists, a subset of 250 compounds, previously rejected by a very experienced senior medicinal chemist, was added to each of the lists. Most of the 13 medicinal chemists who participated in this process reviewed two lists, although some only reviewed a single list and one reviewed three lists. Those compounds that were deemed unacceptable were recorded and tabulated in various ways to assess the consistency of the reviews. It was found that medicinal chemists were not very consistent in the compounds they rejected as being undesirable. The inconsistency arises from the subjective analysis that all humans utilize when considering "data sets" of any kind. This has important implications for pharmaceutical project teams where individual medicinal chemists review lists of primary screening hits to identify those compounds suitable for follow-up. Once a compound is removed from a list, it and other structurally similar compounds are effectively removed from further consideration. This can also have an impact on computational chemists who are developing models for assessing the desirability or attractiveness of different classes of compounds for lead discovery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15369393     DOI: 10.1021/jm049740z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  Drug discovery: Chemical beauty contest.

Authors:  Paul Leeson
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

Review 2.  The influence of the 'organizational factor' on compound quality in drug discovery.

Authors:  Paul D Leeson; Stephen A St-Gallay
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

3.  Quantifying the chemical beauty of drugs.

Authors:  G Richard Bickerton; Gaia V Paolini; Jérémy Besnard; Sorel Muresan; Andrew L Hopkins
Journal:  Nat Chem       Date:  2012-01-24       Impact factor: 24.427

Review 4.  Chemical predictive modelling to improve compound quality.

Authors:  John G Cumming; Andrew M Davis; Sorel Muresan; Markus Haeberlein; Hongming Chen
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

Review 5.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

6.  Enhancing the rate of scaffold discovery with diversity-oriented prioritization.

Authors:  S Joshua Swamidass; Bradley T Calhoun; Joshua A Bittker; Nicole E Bodycombe; Paul A Clemons
Journal:  Bioinformatics       Date:  2011-06-17       Impact factor: 6.937

Review 7.  ESKAPEing the labyrinth of antibacterial discovery.

Authors:  Ruben Tommasi; Dean G Brown; Grant K Walkup; John I Manchester; Alita A Miller
Journal:  Nat Rev Drug Discov       Date:  2015-07-03       Impact factor: 84.694

8.  Decision Making in Medicinal Chemistry: The Power of Our Intuition.

Authors:  Laurent Gomez
Journal:  ACS Med Chem Lett       Date:  2018-09-11       Impact factor: 4.345

9.  Utility-aware screening with clique-oriented prioritization.

Authors:  S Joshua Swamidass; Bradley T Calhoun; Joshua A Bittker; Nicole E Bodycombe; Paul A Clemons
Journal:  J Chem Inf Model       Date:  2011-12-20       Impact factor: 4.956

10.  Growing PAINS in academic drug discovery.

Authors:  Adrian Whitty
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.